PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Blueprint Medicines Corporation (BPMC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS09627Y1091
CUSIP09627Y109
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$5.33B
EPS-$8.37
Revenue (TTM)$249.38M
Gross Profit (TTM)$177.28M
EBITDA (TTM)-$474.61M
Year Range$41.54 - $101.00
Target Price$97.38
Short %11.28%
Short Ratio5.33

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with BPMC

Blueprint Medicines Corporation

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Blueprint Medicines Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%200.00%300.00%400.00%OctoberNovemberDecember2024FebruaryMarch
402.33%
151.66%
BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

S&P 500

Returns By Period

Blueprint Medicines Corporation had a return of 2.76% year-to-date (YTD) and 122.67% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date2.76%10.04%
1 month-0.27%3.53%
6 months89.85%22.79%
1 year122.67%32.16%
5 years (annualized)3.45%13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-13.78%17.59%
2023-24.45%0.72%17.20%18.31%32.45%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Blueprint Medicines Corporation (BPMC) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
BPMC
Blueprint Medicines Corporation
2.08
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Blueprint Medicines Corporation Sharpe ratio is 2.08. A Sharpe ratio higher than 2.0 is considered very good.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
2.08
2.76
BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Blueprint Medicines Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-23.85%
0
BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Blueprint Medicines Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Blueprint Medicines Corporation was 69.50%, occurring on Feb 24, 2023. The portfolio has not yet recovered.

The current Blueprint Medicines Corporation drawdown is 23.85%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-69.5%Dec 24, 2020545Feb 24, 2023
-62.86%Jun 19, 2015161Feb 8, 2016198Nov 17, 2016359
-55.74%Mar 16, 2018195Dec 21, 2018459Oct 19, 2020654
-32.79%Nov 25, 201613Dec 13, 201659Mar 10, 201772
-27.1%May 2, 201720May 30, 201718Jun 23, 201738

Volatility

Volatility Chart

The current Blueprint Medicines Corporation volatility is 12.71%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%OctoberNovemberDecember2024FebruaryMarch
12.71%
2.82%
BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Blueprint Medicines Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items